Company intelligence / Profile preview

Tianjin Kinnovata Pharmaceutical

Tianjin, Tianjin, China

Ownership: Private
Development stage: Other

Overview

Tianjin Kinnovata Pharmaceutical focuses on the development, manufacturing, and commercialization of inhaled drugs, specifically dry powder inhalers, for asthma and COPD. Established in 2013 as a joint venture, the company aims to address the unmet need for affordable and locally produced respiratory therapies in China and Asia. Its initial product candidates, including salbutamol and budesonide, utilize Vectura’s Clickhaler and Duohaler technology platforms. The pipeline is currently in early stages, with no reported late-stage clinical results.

Therapeutic areas: Pulmonology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

VecturaTianjin KingYork GroupZendex Bio StrategyShanghai Institute of Pharmaceutical Industry

Beyond the preview

Go deeper on Tianjin Kinnovata Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Kinnovata Pharmaceutical.

Explore the full profile